On August 23, 2019, the FamilieSCN2A Foundation held their biennial SCN2A Professional and Family meeting, in Seattle, Washington. The gathering brought together 37 families of individuals with mutations in the SCN2A gene, 60 investigators, eight clinicians and five industry groups that conduct research and/or clinical work on conditions related to this genetic change. A number of SFARI scientists and staff also attended the event.
The SCN2A family meeting was one of many events that family organizations of rare, neurodevelopmental disorders organized last summer. These meetings help families connect with others similarly affected as well as professionals working to better understand these conditions and develop new therapeutics. SFARI often attends and facilitates research opportunities carried on at these events.
SCN2A is a high-confidence autism risk gene, which encodes a subunit of a sodium channel in the brain called Nav1.2. When the channel malfunctions, conditions like epilepsy and autism follow. As part of its mission to understand the genetics and neurobiological underpinnings of autism, SFARI has awarded about $3 million for research on SCN2A, and some of this research was presented at the meeting. SFARI also supports a genetics first initiative called Simons Searchlight (formerly known as Simons VIP), which enrolls people with a genetic diagnosis showing rare genetic changes associated with autism and related neurodevelopmental conditions, such as SCN2A.
Many stories that may reflect the different ways SCN2A can be disabled were told at the meeting. One child had his first seizure when he was days old, and now spends many of his days irritable and immobilized by dystonia. Another developed normally until his first seizure as a toddler, which seemed to wipe out all of his skills; his milestones are now hard won in the face of continuing seizures and an autism diagnosis. Another had a sudden regression at 1 year of age, and after a misdiagnosis and seizure medication, she goes to a school for children with autism. Still another suffered from relentless seizures, which robbed her of speech; she died last year at the age of 12.
So far, about 300 different variants of the SCN2A gene have beendocumented, and the functional consequences of many are unclear. Some researchers have developed high-throughput experiments to systematically test each of thesevariants, and to screen compounds that could normalize their function2. Another approach may use genetherapy to boostexpression of the remaining good copy of SCN2A. Either way, finding appropriate in vitro testing grounds for these SCN2A variants is essential and may help personalize treatment approaches or identify more homogeneous patient groups for drug trials.
The meeting also underscored the power of family gatherings to push the science ahead. Investigators could see multiple examples of a rare genetic condition and engage new participants in research studies such as The Investigation of Genetic Exome Research (TIGER), a project of the University of Washington that compares phenotypes of single-gene conditions. In turn, families had the opportunity to express their concerns to scientists and infuse the research proceedings with urgency.
My biggest takeaway from this years conference was the mutual inspiration between the scientists and the families, says Leah Schust, meeting organizer and executive director of the FamilieSCN2A Foundation. Her son has a mutation in SCN2A.
Meeting the researchers working on a cure for our kids motivates us to fight on, Schust says. Then the scientists all say that meeting the families inspires them to go back to their labs and work even harder.
Family focus. The family meeting helped researchers reconsider what would be meaningful clinical endpoints for potential treatments. Schust says that most researchers and industry groups had thought seizure control was the most important issue. After listening to us, they realized that quality of life, movement disorders and autonomic dysfunction are higher on our list of where we would like to see improvement, she says.
When SCN2A mutations were first linked to autism, the gene stood out because it encodes a relatively well-understood protein, unlike many of the other identified genes. Nav1.2 is a voltage-gated channel found exclusively on excitatory neurons in the brain, where it controls the flow of sodium ions into the neuron, and thus its propensity for firing action potential. Experiments have revealed detailed pictures of Nav1.2s structure3, and known drugs alter its function4.
SCN2A also stands out because of its high recurrence rate in autism: unlike other autism genes, SCN2A is mutated with somewhat regular frequency5 (Figure 1).
Just as understanding why a car wont start is critical to fixing it, researchers need to understand how these SCN2A mutations alter the Nav1.2 channel. A current model1 posits that some mutations are gain-of-function, rendering the channel too active and the brain hyperexcitable, leading to infantile epilepsy; conversely, loss-of-function mutations reduce excitability and seem associated with autism and/or intellectual disability, as well as childhood-onset (as opposed to neonatal) seizures.
Yet the functional consequences of most SCN2A mutations remain unknown, and some may not fall neatly into a loss-of-function or gain-of-function category. A way of making sense of these mutations may come from looking at the working parts of Nav1.2, said Arthur Campbell of the Broad Institute of MIT and Harvard. For example, missense SCN2A variants linked to epilepsy seem to hit the channel randomly. But when marking their location on a crystal structure model of the channel, the missense variants cluster in several places: on the voltage sensor, on the linker helix responsible for conveying voltage sensor movement to the channel pore, on an area thought to interact with the beta-subunits involved in chaperoning the channel to the right place, and on the inactivation gate, which closes the pore off from sodium ion flow. He suggested that this knowledge, combined with the structural similarities between all sodium channels, may help drug development for SCN2A-related conditions.
High-throughput systems that can assay hundreds of cells at a time are helping researchers systematically explore SCN2A mutation, explained SFARI Investigator Al George of Northwestern University. While conventional electrophysiology would require weeks of work to characterize a single SCN2A variant, Georges group uses an automated patch-clamp system that can characterize multiple variants transfected into non-neuronal cell lines in a day. Using this system, two variants associated with neonatal seizures both exhibited an exceptional willingness to activate and a slowness to inactivate, which are properties consistent with a gain-of-function interpretation.
The high-throughput set up also promises to expedite the hunt for drugs to normalize SCN2A function: George described a 384-well plate design that allows measurement of the effects of two different drugs, at four different concentrations, on the SCN2A variant and control channels simultaneously. A known drug (carbamazepine) and an experimental drug (PRX-330) shifted channel inactivation to more hyperpolarized voltages, which could help quiet channels with gain-of-function mutations.
To narrow in on potentially therapeutic compounds, Jeff Cottrell and colleagues at the Broad Institute of MIT and Harvard have come up with a two-stage screen to find small molecule activators or inhibitors of Nav1.2 channels. First, compounds are initially tested on non-neural cells transfected with Nav1.2 sodium channels and potassium channels, which enables them to spike. The cells in 384-well plates are stimulated in parallel, and voltage-sensitive dyes give a readout of spiking activity; remarkably, Cottrells system allows data collection from up to 96 wells simultaneously. Any compounds that modulate spiking would then be subjected to the second stage, in a high-throughput electrophysiology assay similar to that described by George. Compounds with helpful mechanisms would then be tested for selectivity for Nav1.2 versus other sodium channels. A selective compound would then be tested in neurons, first in vitro then in vivo. This step-wise process has identified an activating compound that makes Nav1.2 more likely to open at rest and has potent effects on action potentials in brain slices and on electroencephalogram (EEG) traces from mice engineered to carry a disabled copy of SCN2A; however, Cottrell said this particular compound is not a therapeutic candidate in part because it broadens the action potential in a way that could promote seizures. A full screen is underway, and so far has identified 378 modulators from a library of 77,000 compounds.
Beyond academia, J.P. Johnson Jr. of Xenon in Burnaby, British Columbia, discussed the companys work to create sodium channel inhibitors for treating epilepsy. To obtain selective compounds, the group targets the voltage-sensing domain because its structure is the most diverse region of sodium channels. Xenon uses a trial-and-error method to optimize sodium channel inhibitor potency and selectivity. The methodical process has yielded some interesting compounds, including both selective Nav1.6 inhibitors and dual Nav1.6 and Nav1.2 inhibitors. Both quashed spiking in mouse excitatory pyramidal neurons, which contain only Nav1.2 and Nav1.6, but they did not alter spiking in Nav1.1-containing inhibitory neurons. A Nav1.6 selective inhibitor, XEN901, is currently undergoing safety trials in humans.
Kathrin Meyer of Nationwide Childrens Hospital in Columbus, Ohio, addressed the possibility of using gene therapy to normalize malfunctioning Nav1.2 channels. Meyer has been involved in several gene-therapy trials for neuromuscular disorders, including a successful one for infant-onset spinal muscular atrophy type6. Gene therapy for brain diseases was spurred by the discovery of adeno-associated virus 9 (AAV9), which can cross the bloodbrain barrier to deliver genetic material to the central nervous system. AAV9 is small, cannot replicate, does not integrate into host DNA and seems not to cause disease in humans. In considering gene therapy for SCN2A-related conditions, Meyer emphasized an approach that adds back a working copy of the gene, thus sidestepping the need for gene editing to make mutation-specific corrections. Such a treatment would only apply to those with loss-of-function mutations.
The large size of the SCN2A gene precludes its delivery by AAV9, however. As a workaround, Meyer suggested that SCN2As mRNA transcript could be targeted in an attempt to replace only the affected area of the mRNA. So far, such strategies have not been very efficient, but there are new ideas that might address some of the difficulties. Because access to tissue samples of patients with neurological disorders is limited, the development and testing of new therapies is complicated. Meyer suggested developing gene therapies in vitro using neurons reprogrammed from skin cells of patients. This might help identify which patients would react best to a certain treatment. There is likely not a one-fit-for-all situation, she said.
SFARI deputy scientific director John Spiro underscored the need for in vitro systems, citing the organizations initiative to bank blood cells to systematically generate induced pluripotent stem cells from individuals with autism. Simons Searchlight is also a resource of many different biospecimens for researchers. So far, 186 families with SCN2A-related changes have registered, and 83 of these have completed consent, lab reports and medical histories with a large number of blood samples as well. (On the sidelines of the meeting, 18 parents, 11 of their children with SCN2A mutations, and three unaffected siblings donated blood toward this initiative.) Spiro also stressed a need to come up with more quantitative methods of phenotyping, such as wearable electronics that can monitor sleep and circadian rhythms. Data that can be collected longitudinally and at home might provide sensitive outcome measures for clinical trials.
A new role for Nav1.2 has been revealed in recent work described by SFARI Investigator Kevin Bender of the University of California, San Francisco: the channels mediate back-propagating action potentials, which travel into the dendritic trees of neurons. Mice engineered to lack one copy of SCN2A a situation that mimics people with truncating SCN2A mutations that render the resulting Nav1.2 channels useless had cortical neurons with slower action potentials, reduced dendritic excitability and immature synapses based on their shape and function7. This role for Nav1.2 was particularly important later in development: when conditional knockout mice lost an SCN2A copy later in life, their cortical neurons exhibited immature synapses, though their density remained normal. Preliminary experiments suggest that adding back a working copy of SCN2A later in life through transgenic methods or by upregulating transcription of the remaining good copy of SCN2A via CRISPR techniques can restore action potential velocity and synaptic maturity.
Bender stressed how interacting with the SCN2A family group helped focus his research on important aspects of their childrens conditions. For example, parents have noted sensory hypersensitivity in their children, leading Bender to collaborate with colleague Evan Feinberg to use an eye-tracking assay in mice to measure their visual responses. He noted that SCN2A haploinsufficient mice were more sensitive to certain visual stimuli than control mice; if the assay is robust, it could help bridge the gap between SCN2A-related phenotypes in humans and behaviors measured in mice.
As meeting attendees sorted through the new findings, therapeutic questions lingered. An important issue for any therapy, whether drug or gene, will be how early in development one will have to intervene to help someone with an SCN2A mutation. Bender noted that synaptic properties could be rescued in his mice when they were 30 days old equivalent to a 10-year-old human but these and other experiments will have to probe the time periods during which therapies will be maximally effective. To find good measures of efficacy also means understanding the full complement of conditions that beset people with SCN2A mutations. For example, though seizures afflict many, Keith Coffman of Childrens Mercy Hospital in Kansas City, Missouri, suggested that, in some cases, these represent a movement disorder rather than epilepsy. Basic descriptive knowledge like this is imperative for guiding future treatment approaches.
Another smaller SCN2A meeting is planned for this year from July 30 to August 2, in Columbus, Ohio. This will be more family focused, says Schust, and there will be opportunities to participate in research.
There is clearly a lot more work to do before all the terrific basic research that was discussed at this meeting produces meaningful results for families, but it is extremely gratifying to see how much progress has been made on so many fronts and how many new good ideas are emerging, Spiro says. And its terrific to witness firsthand the positive cycle of how families drive researchers and vice versa.
Originally posted here:
Seeing through a forest of SCN2A gene variation - SFARI News
- Kansas City MO Resources - Stem Cells: Get Facts on Uses ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cell History | A History of Stem Cell Research [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Midwest Stem Cell Therapy Center, University of Kansas ... [Last Updated On: September 1st, 2014] [Originally Added On: September 1st, 2014]
- Stowers Researchers Reveal Molecular Competition Drives ... [Last Updated On: September 6th, 2014] [Originally Added On: September 6th, 2014]
- Precise and programmable biological circuits [Last Updated On: October 24th, 2014] [Originally Added On: October 24th, 2014]
- Myocardial infarction and stem cells - National Center for ... [Last Updated On: October 31st, 2014] [Originally Added On: October 31st, 2014]
- Advisory Board, Midwest Stem Cell Therapy Center [Last Updated On: November 2nd, 2014] [Originally Added On: November 2nd, 2014]
- Therapeutic potential of human induced pluripotent stem ... [Last Updated On: November 5th, 2014] [Originally Added On: November 5th, 2014]
- Exploring Stem Cell Therapy for Cerebral Palsy | See the Seitz [Last Updated On: December 12th, 2014] [Originally Added On: December 12th, 2014]
- Saint Lukes Mid America Heart Institute Offers Tips & Treatments For Heart Failure Awareness Week 2015 [Last Updated On: February 10th, 2015] [Originally Added On: February 10th, 2015]
- Topeka retailer honored as 'business of the year' [Last Updated On: March 7th, 2015] [Originally Added On: March 7th, 2015]
- Stem Cells for Paralysis: First of Its Kind Study [Last Updated On: April 7th, 2015] [Originally Added On: April 7th, 2015]
- Doctors in Kansas who treat or diagnose Stem Cell Transplant [Last Updated On: August 1st, 2015] [Originally Added On: August 1st, 2015]
- Egg Stem Cells - MIT Technology Review [Last Updated On: September 27th, 2015] [Originally Added On: September 27th, 2015]
- Kansas Regenerative Medicine Center [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Stem Cell Therapy for Urological Issues | Kansas RMC [Last Updated On: July 29th, 2016] [Originally Added On: July 29th, 2016]
- Stem cell program - University of Kansas Medical Center [Last Updated On: August 3rd, 2016] [Originally Added On: August 3rd, 2016]
- Kansas to Build First US Stem Cell Research Center | CorCell [Last Updated On: August 3rd, 2016] [Originally Added On: August 3rd, 2016]
- Stem Cell Therapy | Kansas RMC [Last Updated On: August 3rd, 2016] [Originally Added On: August 3rd, 2016]
- Stem Cell Therapy - North Kansas City Hospital, Kansas ... [Last Updated On: October 14th, 2016] [Originally Added On: October 14th, 2016]
- Stem Cell Collection - University of Kansas Hospital [Last Updated On: October 30th, 2016] [Originally Added On: October 30th, 2016]
- International Space Station's Crew Restored to Six People - Kansas City infoZine [Last Updated On: July 30th, 2017] [Originally Added On: July 30th, 2017]
- Scientists build DNA from scratch to alter life's blueprint - Kansas City Star [Last Updated On: July 30th, 2017] [Originally Added On: July 30th, 2017]
- Regenerative Medicine Market in the US - Forecasts, Segmentation, and Opportunity Assessment by Technavio - Business Wire (press release) [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Join Jon Kempin, LA Galaxy Foundation and Gift of Life Marrow Registry for Kick Blood Cancer on August 13 - LA Galaxy [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
- Paralyzed after pool accident, student heads back to college - Kansas City Star [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- About Us, Midwest Stem Cell Therapy Center - KUMC [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Feared Zika virus kills brain cancer stem cells, new research shows - Kansas City Star [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
- Shawnee Woman Was Among First In The World To Undergo New FDA-Approved Cancer Therapy - KCUR [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
- Regenexx Kansas City | Helping your body heal itself [Last Updated On: September 24th, 2017] [Originally Added On: September 24th, 2017]
- Future Fertility Fix? Egg-Producing Stem Cells Found in ... [Last Updated On: October 14th, 2017] [Originally Added On: October 14th, 2017]
- Stem cells or Knee surgery - Kansas Regenerative Medicine [Last Updated On: June 28th, 2018] [Originally Added On: June 28th, 2018]
- Adult Stem Cell Therapy 101, MSCTC - University of Kansas ... [Last Updated On: July 7th, 2018] [Originally Added On: July 7th, 2018]
- Stem cells relieve chronic pain in Kansas City, MO [Last Updated On: July 30th, 2018] [Originally Added On: July 30th, 2018]
- Knee Stem Cell Treatments in Kansas City | Motus Biologics [Last Updated On: August 2nd, 2018] [Originally Added On: August 2nd, 2018]
- Kansas Stem Cell Center Close To First Clinical Trial | KCUR [Last Updated On: August 27th, 2018] [Originally Added On: August 27th, 2018]
- Stem Cell Therapy in Wichita, Kansas | Joint Pain Relief ... [Last Updated On: October 6th, 2018] [Originally Added On: October 6th, 2018]
- About Stem Cell Therapy - Kansas Regenerative Medicine [Last Updated On: November 29th, 2018] [Originally Added On: November 29th, 2018]
- Hip Stem Cell Treatment | Motus Biologics in Kansas City [Last Updated On: January 23rd, 2019] [Originally Added On: January 23rd, 2019]
- Stem Cell Therapy in Kansas City- Rejuvenate KC | Stem ... [Last Updated On: April 26th, 2019] [Originally Added On: April 26th, 2019]
- Stem Cell Procedures | Motus Biologics of Kansas City [Last Updated On: September 9th, 2019] [Originally Added On: September 9th, 2019]
- Kansas Regenerative Stem Cell Seminar - Stem Cell Centers ... [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- Infanticide: Live Organ Harvesting Commonplace in US Abortion Mills - Church Militant [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- Trial cancer treatment in Wichita - KAKE [Last Updated On: December 2nd, 2019] [Originally Added On: December 2nd, 2019]
- FHSU partners with Be the Match for bone marrow registry event - hays Post [Last Updated On: February 20th, 2020] [Originally Added On: February 20th, 2020]
- Incysus Therapeutics Announces Name Change to IN8bio, Inc. - GlobeNewswire [Last Updated On: August 28th, 2020] [Originally Added On: August 28th, 2020]
- IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio's Gamma Delta T-cell product... [Last Updated On: December 4th, 2020] [Originally Added On: December 4th, 2020]
- [Full text] Binding of the SARS-CoV-2 Spike Protein | HMER - Dove Medical Press [Last Updated On: April 15th, 2021] [Originally Added On: April 15th, 2021]
- Kelly lauds $21 billion state budget bill, vetoes $500,000 ... [Last Updated On: June 6th, 2021] [Originally Added On: June 6th, 2021]
- The controversy being created about the origins of the virus that causes COVID-19 - Frontline [Last Updated On: July 6th, 2021] [Originally Added On: July 6th, 2021]
- COVID-19 directly damages, creates scar tissue on the kidneys, study finds - WDAF FOX4 Kansas City [Last Updated On: January 5th, 2022] [Originally Added On: January 5th, 2022]
- Four researchers named recipients of the University Scholarly Achievement Award | The University of Kansas - KU Today [Last Updated On: March 25th, 2022] [Originally Added On: March 25th, 2022]
- Jayhawks shine at 2022 Capitol Graduate Research Summit | The University of Kansas - KU Today [Last Updated On: April 19th, 2022] [Originally Added On: April 19th, 2022]
- Chemical Markers That May Unlock Future Therapeutic Uses of mRNA - Lab Manager Magazine [Last Updated On: May 2nd, 2022] [Originally Added On: May 2nd, 2022]
- The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies - Neurology Live [Last Updated On: June 22nd, 2022] [Originally Added On: June 22nd, 2022]
- Doctors Transplant Kidneys to Children Without Need for Immune ... [Last Updated On: July 11th, 2022] [Originally Added On: July 11th, 2022]
- California is poised to phase out sales of new gas-powered cars - Kansas Public Radio [Last Updated On: August 30th, 2022] [Originally Added On: August 30th, 2022]
- Human cells in a rat's brain could shed light on autism and ADHD - Kansas Public Radio [Last Updated On: October 13th, 2022] [Originally Added On: October 13th, 2022]